<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1001">
  <stage>Registered</stage>
  <submitdate>16/01/2006</submitdate>
  <approvaldate>14/06/2006</approvaldate>
  <actrnumber>ACTRN12606000236594</actrnumber>
  <trial_identification>
    <studytitle>Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow Phenomenon</studytitle>
    <scientifictitle>Placebo controlled, randomised, crossover study of the efficacy of dipyridamole in reducing the number of angina episodes in patients with Coronary Slow Flow Phenomenon (CSFP)</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Slow Flow Phenomenon</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dipyridamole 200mgs orally twice daily for 10 weeks ie 5 weeks of each treatment blinded.After 5 weeks of treatment patients would cross over to opposite treatment.Patients and study staff(excluding study pharmacist) remain blinded to the study drug throughout the duration of the study.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Angina frequency (total number of episodes of chest pain as recorded in a diary by the patient)</outcome>
      <timepoint>Measured and recorded at the end of each of the 2 phases</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nitrate consumption.</outcome>
      <timepoint>Measured at the end of each of the 2 phases.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life indices.</outcome>
      <timepoint>Measured at the end of each of the 2 phases.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Coronary slow flow phenomenon.  Frequent angina(&gt; 3 episodes per week).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Significant haemorrhagic risk.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers allocated to patients via fax to unblinded pharmacist</concealment>
    <sequence>Sequence generated via computer in permuted blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/10/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital,Cardiology Unit</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Queen Elizabeth Hospital,Cardiology Unit</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Boehringer Ingelheim</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Germany</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess if dipyridamole reduces the frequency of angina in patient with CSFP.
Study pharmacist was the only person unblinded to study treatment. Blinding was achieved by using pre numbered study drug containers and by fax randomisation to study pharmacist who would then allocate the study drug to the patient who is also blinded</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabath Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/01/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Rd 
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227021</fax>
      <email>sue.leslie@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Rd 
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227201</fax>
      <email>sue.leslie@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>